Across 79 glioblastoma/glioma Phase I–III trials, the strongest recurring site footprint is led by Universitaetsklinikum Heidelberg AöR and Hospital Universitari Vall D Hebron, each appearing in 13 distinct trial-site participations. France is the largest country platform with 190 site placements and 2,408 planned patients, while small molecules remain the dominant modality in 54 trials.
The top 10 listed sites accounted for 103/639 site-trial participations (16.1%). Universitaetsklinikum Heidelberg AöR and Hospital Universitari Vall D Hebron led the ranking with 13 distinct trial participations each, followed by Centre Hospitalier Regional De Marseille with 12.
The top tier is not a single-country cluster: Germany, Spain, France, Denmark, and Norway all appear in the leading group. Operationally, the strongest recurring sites are broad neuro-oncology platforms rather than phase-specific centers, since every top-10 site appears across Phase I, II, and III cohorts.
Across the included trials, country-level enrollment sums to 7,277 planned patients and 657 site placements. France led with 2,408/7,277 patients (33.1%) and 190/657 sites (28.9%), followed by Germany with 1,401 patients and 146 sites.
France and Germany together represented 3,809/7,277 planned patients (52.3%). The top five countries represented 5,419/7,277 patients (74.5%) and 522/657 site placements (79.5%), making country selection a major driver of glioblastoma recruitment capacity.
Glioblastoma / GBM was the largest disease segment with 51/79 trials (64.6%), 367/657 site placements (55.9%), and 4,152/7,277 planned patients (57.1%). The next largest patient segment was IDH-mutant / grade 2–3 glioma with 1,133 patients.
The dataset is anchored by adult glioblastoma/GBM studies, but the non-GBM glioma market is operationally meaningful: diffuse midline glioma/DIPG, low-grade glioma, IDH-mutant glioma, and high-grade glioma together account for 28 trials and 3,125 planned patients.
Small molecules were present in 54/79 trials (68.4%), making them the dominant modality. Monoclonal antibodies appeared in 14/79 trials (17.7%), while radiopharmaceuticals and cell therapies appeared in 7 and 6 trials respectively. Combination treatment was present in 55/79 trials (69.6%).
The modality mix shows a conventional backbone with targeted and immune additions rather than a wholesale shift to advanced therapies. Temozolomide appeared in 22 trials and lomustine in 7, indicating that many studies still build around established neuro-oncology comparators or combination partners.
Phase II was the largest phase involvement group with 43/79 trials (54.4%), followed by Phase I with 36/79 (45.6%) and Phase III with 27/79 (34.2%). By authorization-year cohort, 53/79 trials (67.1%) were in 2024, 21/79 (26.6%) in 2025, and 5/79 (6.3%) in 2026.
Phase II is the operational center of gravity, but Phase III still represents the largest patient footprint by phase involvement, with 3,789 planned patients. That pattern suggests a field with active exploratory development and a smaller number of large late-stage recruitment programs.
Oncology-only trials accounted for 56/79 trials (70.9%). Oncology plus neurology appeared in 12/79 trials (15.2%), while paediatric trials represented 20/79 (25.3%) and orphan-context trials represented 12/79 (15.2%).
Glioblastoma and glioma trial operations are mostly oncology-led, but a meaningful subset crosses into neurology and paediatric neuro-oncology. This explains why the top-site list mixes oncology departments, neuro-oncology units, neurology services, and paediatric oncology centers.